

Twenty-First Century Pharmaceutical Development

Peter Blaisdell
Editor

R91
T971

Twenty-First Century Pharmaceutical Development

Peter Blaisdell

Editor



E200300193

Interpharm Press
Denver, Colorado



Invitation to Authors



Interpharm Press publishes books focused upon applied technology and regulatory affairs impacting healthcare manufacturers worldwide. If you are considering writing or contributing to a book applicable to the pharmaceutical, biotechnology, medical device, diagnostic, cosmetic, or veterinary medicine manufacturing industries, please contact our director of publications.

Library of Congress Cataloging-in-Publication Data

Twenty-first century pharmaceutical development / Peter Blaisdell, editor.

p. ; cm.

Includes bibliographical references and index.

ISBN 1-57491-102-3

1. Drug development. 2. Pharmaceutical industry. I. Blaisdell, Peter.

[DNLM: 1. Drug Industry. 2. Research. QV 736 T971 2000]

RM301.25 .T94 2000

615'.19—dc21

00-059679

10 9 8 7 6 5 4 3 2 1

ISBN: 1-57491-102-3

Copyright © 2001 by Interpharm Press. All rights reserved.

All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America.

Where a product trademark, registration mark, or other protected mark is made in the text, ownership of the mark remains with the lawful owner of the mark. No claim, intentional or otherwise, is made by reference to any such marks in this book.

While every effort has been made by Interpharm Press to ensure the accuracy of the information contained in this book, this organization accepts no responsibility for errors or omissions.

Interpharm Press
15 Inverness Way E.
Englewood, CO 80112-5776, USA

Phone: +1-303-662-9101
Fax: +1-303-754-3953
Orders/on-line catalog:
www.interpharm.com

Introduction

Peter Blaisdell

The past century has seen a phenomenal application of advances in basic science for the development of pharmaceuticals, diagnostics, and medical devices. However, this will pale relative to the advances that will occur in the twenty-first century as further progress is made in understanding molecular biology and physiology. One manifestation of this progress is the sequencing of the entire human genome. In combination with continued progress in understanding gene expression and function, this will create new opportunities for diagnosis and therapeutic intervention. Morbidity and mortality associated with cancer, cardiovascular disease, infections, diabetes, and aging itself will become ever more amenable to treatment.

Facilitating the commercialization of scientific discoveries has been the evolution of a process for drug development over the past several decades. This process includes activities leading from the research lab to a marketable product. In coming decades, the development process will be influenced by several factors, including the standardization of government regulations controlling drug development across the major markets for pharmaceuticals—North America, Europe, and Japan. South America, China, and other parts of Asia will probably adopt similar regulations to create a relatively homogeneous global environment for therapeutic development within the next decade or two. Further, these same governments are likely to insist on becoming even more involved than they currently are in controlling drug costs to consumers. This will challenge the pharmaceutical industry to develop pricing strategies that can survive government scrutiny while preserving enough corporate profits to fund the expensive and uncertain pharmaceutical research process.

Future drug development will also be influenced by the continued consolidation of global pharmaceutical businesses into ever-larger entities. Currently, no one corporation controls even 10 percent of the total pharmaceutical market. However, this will likely change as large players merge.

Increased size will allow for efficiencies in the marketing, manufacturing, and regulatory efforts needed to launch a new drug globally. Whether size alone will also lead to efficiencies in the pharmaceutical research effort remains to be seen. Certainly, in the later twentieth century, some small biotechnology firms proved adept at exploiting basic biological research on shoestring budgets by narrowly focusing on developing products for a single therapeutic area and outsourcing parts of the development effort. Whether such small companies continue to play an important role in developing drugs will be a critical factor in defining how pharmaceuticals are developed in coming decades.

This book, *Twenty-First Century Pharmaceutical Development*, provides an overview of how key aspects of the drug development process currently work and how they may be done in the future. The book is organized generally to reflect the various functional disciplines involved in the development of drugs, with chapters describing each of these areas. Clearly, some disciplines, such as basic research, are likely to experience great changes in the next few decades, but all functional areas are evolving as the advances in basic science allow fundamental health issues to be addressed.

The first chapter reviews financing strategies with a particular emphasis on issues critical for smaller drug companies. Creating therapeutics takes piles of cash; developing a drug from the basic research phase through international market launch may cost several hundred million dollars. Medical devices and diagnostics are usually less expensive than drugs, since they can require fewer clinical studies to confirm their safety and efficacy, but they, too, are costly to bring to market. For large drug developers, funding for future therapies is derived from current product profits. However, for smaller firms, with innovative technologies but modest financial resources, amassing the money needed to undertake the development process is critically dependent on external sources of funding. In the last 20 years, there have been mechanisms for providing such funding including venture capital firms (many with addresses on Sand Hill Road in Menlo Park, Calif.) willing to finance small pharmaceutical companies in return for high rates of return. By necessity, these sources of funding have had to be quite risk tolerant, as many drug development efforts fail. Because small pharma has been adept at converting cutting edge technology into new products—in many cases, more adept than large multinational drug companies—the accessibility of financing has been a key factor in growing the pharmaceutical sector. However, it is uncertain whether small drug firms can continue to avail themselves of such funding in the twenty-first century given competing opportunities in other, less heavily regulated technology sectors such as computer and communications development that offer faster returns on an investment. The chapter on financing reviews strategies to generate financing in this changing environment.

The core of pharmaceutical development is research, both at the discovery phase when new therapeutics are being identified and at the preclinical and clinical phases when the new therapeutics are assessed in animals and humans for safety and efficacy. *Twenty-First Century Pharmaceutical Devel-*

opment therefore devotes extensive chapters to each of these phases. The chapter on discovery research describes several current approaches to identifying genes of interest and their functions. This chapter also explores current methodologies for rapidly screening new leads for therapeutic utility against human diseases. An overview of gene therapy is also provided. Managing research efficiently without stifling creativity will be a central challenge in the new century.

Once a potential new product has shown promise during the initial screening process, it will be further tested in appropriate animal species to gauge its utility and safety in humans. The chapter on preclinical research provides an overview of both the current battery of animal trials used to determine a new lead compound's toxicology profile as well as describing promising new *in vitro* and *in vivo* methods that may replace or at least reduce the need for traditional safety testing in animals. If proven successful, these new methods have the potential to reduce both the cost and time needed for this stage of the development process.

The chapter on clinical research focuses on developing and implementing a clinical strategy that is consistent with overall corporate goals. It presents a detailed template to assist in aligning the development of a clinical program with the desired label claims and existing knowledge about the potential product's preclinical characteristics. Tools such as this will likely become more common as pharmaceutical firms struggle to balance speed of development with the need to conduct high-quality studies.

No description of the research phase of the drug development process would be complete without a description of the role applied statistics plays in clinical trial design. Thus, a chapter on biostatistics is included in this book to provide a statistical perspective on trial structure, inclusion of control groups, randomization, and sizing a study.

In concert with research activities to discover and develop a promising therapeutic, a pharmaceutical firm must also implement effective legal, marketing, and regulatory strategies. A chapter describes each of these specialties. Very early in the development process, the patent position of the promising new lead must be confirmed. The characteristics of patents are described in the chapter on intellectual property along with an overview of infringement and inventorship. The chapter also discusses how a robust intellectual property strategy will contribute to competitive advantage in the new century. Likewise, a clear regulatory strategy is critical in efficiently developing a new pharmaceutical product. The chapter on the regulatory process summarizes both the current Investigational New Drug/New Drug Application (IND/NDA) process as well as evolving trends toward paperless submissions, increased use of the internet to facilitate communications between the sponsor and the agency, and the efforts to harmonize regulatory standards globally.

Without a clear sense of the market for a potential product, the best drug development effort will be of limited value, producing a therapeutic or device that is not aligned with a patient population's needs. As described in the

chapter on selling pharmaceuticals, the traditional four P's of marketing—product, place, price, and promotion—are critical in selling drugs today and will continue to be important in the foreseeable future. However, understanding new factors affecting the twenty-first century pharmaceutical market will also be critical. One trend already well underway will be the aging of populations in the largest current markets, North America, Europe, and Japan, resulting in shifts in the types of therapeutics demanded by these consumers, most of whom receive medical payment support from their respective governments. However, therapeutic needs will also grow in younger but less affluent developing markets. In conjunction with these trends will almost certainly be increased efforts by governments and private healthcare providers to contain therapeutic costs. Another trend affecting drug marketing will be the Internet's role in supplementing established means of communicating a product's benefits to the target population as well as facilitating the dialogue between the pharmaceutical manufacturer and the patient. Clearly, the already intricate process of selling pharmaceuticals will become more complex in the new century.

Producing a drug in the form and quantity needed is, of course, essential. Therefore, two chapters describe the functions of formulation and manufacturing in the drug development process. Almost as soon as a potential new product is discovered, consideration needs to be given to an appropriate formulation - and the choices available are increasing. Traditional parenteral options including intravenous, subcutaneous, and intramuscular as well as liquid and solid oral formulations will continue to be important in many development efforts. However, new modes of formulation, including inhalation, transdermal, and other technologies, may offer more efficient means to deliver a given therapeutic. Formulations that can be targeted effectively may limit the "collateral damage" the patient incurs from the nonspecific effects of a given drug.

For a successful development effort, manufacturing should work closely with the formulation group. In addition to the classic challenges of scale-up and assuring consistency that pharmaceutical manufacturing has always faced with small molecules, the production of biopharmaceuticals will add further complexities as gene therapies need to be produced in large quantities. Of course, this will have to be accomplished in an increasingly heavily regulated environment.

A firm developing drugs or devices can outsource almost any part of the process from preclinical activities through marketing an approved product. Thus, a chapter is devoted to describing contract research organizations (CROs) and presenting factors that a sponsor needs to consider when deciding whether part or all of a developmental effort should be delegated to a CRO. Their use has become common over the last two decades for small and large pharmaceutical firms; despite skepticism on the part of sponsors, the next decade will likely see outsourcing continue as a critical part of development efforts. Drug and device makers are struggling to speed time to market

for new products while simultaneously containing costs. Outsourcing allows the sponsoring firm to avoid adding personnel and facilities while still undertaking many projects at the same time. A case study is also included to illustrate issues that are likely to arise between a sponsor and a CRO during a developmental project.

The activities of the many functional groups involved in developing new therapeutics are conveniently described as individual steps. *Twenty-First Century Pharmaceutical Development* takes this approach. However, pharmaceutical development should be conducted as an integrated team effort. In many drug firms, project management (or a functionally equivalent group) plays the critical role of coordinating activities of disparate groups who may have little appreciation of what their counterparts in other departments are doing. If portions of the project are being outsourced, the task of coordination becomes more complex as both internal and external resources must be meshed. By default, project managers must take a cross-disciplinary approach. Further, in an era of increasing time and budget constraints, project management will play a vital role in tracking and managing project schedules and costs. The chapter on project management describes this evolving role.

The bulk of *Twenty-First Century Pharmaceutical Development* focuses on the drug development process. Though similar in many overall aspects, diagnostic and medical device development are individual disciplines with unique approaches to regulatory, clinical, quality control, and manufacturing. An extensive chapter is devoted to both diagnostics and devices that describes their current development process as well as future trends.

The early decades of the twenty-first century will almost certainly see continued successes in turning basic biological research into exciting pharmaceutical products. Improvements in the drug development process described in this book will be critical in achieving this goal.

Peter Blaisdell, PhD
August 2000

About the Contributors

PETER BLAISDELL, EDITOR

Peter Blaisdell earned his PhD in biochemistry from the University of Minnesota where he also performed postdoctoral research. After completing his studies, he worked in the project management group at Quintiles, coordinating the activities of multifunctional teams developing pharmaceuticals for therapeutic areas including oncology, cardiology, and central nervous system disorders. He currently manages clinical studies in the Clinical Affairs Department of Amgen and teaches graduate courses in technology management at the University of Phoenix and San Francisco State University.

DAVID R. BRISTOL

David Bristol is director of cardiovascular biometrics at the Parke-Davis Pharmaceutical Research Division of Warner-Lambert. He received his PhD in statistics from the State University of New York at Buffalo and has been a statistician in the pharmaceutical industry for over 18 years. During that time, he has held positions of increasing responsibility at Sanofi Pharmaceuticals, Schering-Plough, Janssen, and CIBA-GEIGY. He has authored or coauthored over 30 published papers on statistical methodology, especially in the areas of clinical trials methodology and sample size determination. He is a member of the Biometric Society, the Drug Information Association, the Society for Clinical Trials, the International Chinese Statistical Association, and the American Statistical Association.

SUSAN BURTON

Susan Burton, MBA, is a senior manager of clinical operations at Titan Pharmaceuticals, Inc. She had previously worked at Quintiles Oncology, where she was a project manager. Ms. Burton is a member of the Drug Information Association (DIA).

WOLF-DIETER BUSSE

Wolf-Dieter Busse has a diploma in chemistry and a PhD in macromolecular chemistry and organic chemistry from Technical University, Aachen, Germany. He did postdoctoral work in biochemistry at the University of California, Berkeley. He is currently senior vice president of biotechnology at Bayer Corporation in Berkeley. He previously worked for Bayer AG in Germany as a research scientist and department head. He was president of Molecular Therapeutics, Inc., vice president of research at Molecular Diagnostics, Inc., and head of Miles Research Center for pharmaceutical R&D. Dr. Busse was also the international head of preclinical R&D for the Research Centers Bayer/Miles/Bayer Yakukin in Europe, the United States, and Japan. Dr. Busse is also a professor at the Institute of Genetics at the University of Cologne and a board member of several scientific and health-related organizations.

NADINE CAROL CHIEN

Nadine Chien received her BA from Mount Holyoke College. Following receipt of her PhD in molecular immunology from Albert Einstein College of Medicine, Dr. Chien completed two postdoctoral fellowships in the areas of human genomics and biochemical cellular signal transduction. She obtained her JD from the University of Denver College of Law and has been practicing biotech patent law since 1992. Dr. Chien is currently Director of Intellectual Property and Senior Patent Attorney at Pharmaceutical Product Development, Inc.

TERRENCE C. DAHL

Terrence C. Dahl currently serves as director of formulation and process development at Gilead Sciences, Inc., Foster City, California. Prior to this appointment, he was employed in the Formulation Development group at Syntex Research in Palo Alto, California. He has 15 publications in the form of research papers and monographs. Dr. Dahl holds a BS in pharmacy from

North Dakota State University and a PhD in pharmaceuticals from the University of Iowa. In addition, he is a registered pharmacist in California, Iowa, Montana, and North Dakota.

DIMITRIS DOGRAMATZIS

Dimitris Dogramatzis has devoted his entire education and professional career to the pharmaceutical field. He received a BS in pharmacy from the University of Patras, Greece, a PhD in pharmacology from the University of Texas Medical Branch at Galveston, Texas, and postdoctoral degrees from the University of Texas Medical Branch and the M. D. Anderson Cancer Center in Houston, Texas. His professional career includes pharmaceutical product management, medical affairs marketing, and disease management. He has been the Managing Director of Serono Hellas S.A. since 1997. He is the author of numerous research and business publications.

MATTHEW FRANK

Matthew Frank is the president and founder of MMF Consulting Inc. He previously worked at several companies, including CV Therapeutics, Pharmatec, and Genentech in various financial and management capacities. Mr. Frank holds an MS in management and a BA in human biology, both from Stanford University. He has been a special lecturer for CME credits for physicians. He is a member of several professional organizations.

ROBERT JAMES

Robert James has an extensive background in the development of diagnostic products, with a particular emphasis on the regulatory and quality control issues critical to successful filings. Most recently, he has headed a consulting group providing expertise in these areas to clients conducting both early and late stage diagnostic product development efforts.

MARK PEMBERTON

Mark Pemberton has an MS degree in microbiology and has worked in the fields of fermentation science and biotechnology for the past 24 years. After three years with Gulf Oil Chemical Company working on the conversion of cellulose to ethanol, Mr. Pemberton joined Cetus Corporation in 1979. He has worked in biopharmaceutical manufacturing since 1982 and has been

associated with the introduction of four commercial biotech products: interleukin-2, beta interferon, platelet-derived growth factor, and Menjugate, a vaccine for meningitis C. He has extensive experience in the fields of fermentation, large-scale purification, process validation, GMP, and facility design. Mr. Pemberton is the vice president of manufacturing and operations for Chiron Biopharmaceuticals and is responsible for the operation of three licensed manufacturing plants.

MEGGI RAEDER

Meggi Raeder, PhD, RAC, is the president of Regulatory Solutions, providing consultant services to the pharmaceutical and biotechnology industries. She has 16 years of regulatory experience in the biopharmaceutical industry, mainly focusing on the development of innovative drugs and biologics. Prior to becoming a consultant, she was a regulatory program director at Syntex (now Roche Global Development), Palo Alto, California, and director of clinical and regulatory affairs and quality assurance at Celtrix Pharmaceuticals, Inc., Santa Clara, California. In her function as a regulatory professional, she has been the primary contact between the company and the Food and Drug Administration, and has filed numerous new drug exemptions (INDs) for the initiation of clinical trials and New Drug Applications (NDAs) for the commercialization of new drugs. She has also directed the strategic regulatory planning of drugs and biotechnology development programs nationally and internationally. Prior to Dr. Raeder's career in the pharmaceutical industry, she had been a practicing pharmacist and held a director position at a public pharmacy in Cologne, Germany. Dr. Raeder is a registered pharmacist in Germany and obtained her PhD in pharmaceutical chemistry from the University of California, San Francisco. She is a certified regulatory affairs professional (RAC).

LARRY E. RODMAN

Larry E. Rodman is employed by Sanofi-Synthelabo Research as a principal research investigator in the Department of Toxicology. Dr. Rodman received a PhD in toxicology from the University of Kentucky in 1990 and went on to serve as a study director/toxicologist at Southern Research Institute until 1997, and then with Gilead Sciences, Inc. from 1997 to 2000. He is a Diplomate of the American Board of Toxicology (1995, 2000) and is licensed by the State of Tennessee and the American Society of Clinical Pathologists as a Medical Technologist since 1981. Dr. Rodman is a member of the Society of Toxicology, the American Association for Clinical Chemistry, and the American Society of Clinical Pathologists.

PATRICK J. SCANNON

Patrick J. Scannon, MD, PhD, is founder, chief scientific and medical officer, and member of the Board of Directors of XOMA Ltd. For the past 21 years, Dr. Scannon has had extensive involvement in the clinical testing of biological agents, both at XOMA and Letterman Army Institute of Research. Dr. Scannon holds a PhD in organic chemistry from the University of California, Berkeley, and a medical degree from the Medical College of Georgia. He completed his medicine internship and residency at the Letterman Army Medical Center in San Francisco. A Board-certified internist, Dr. Scannon also is a member of the American College of Physicians.

CHARLES SIDEBOTTOM

Charles Sidebottom received a BSc in electrical engineering in 1968 from Iowa State University and an MSc in electrical engineering from the University of Missouri in 1979. He is a registered professional engineer. Mr. Sidebottom is currently director of corporate standards at Medtronic, Inc., in Minneapolis, Minn. He serves as secretary to the International Electrotechnical Commission subcommittee 62A and is the industry chairman of the AAMI Pacemaker Committee. He is the convener of the IEC working group on cardiac pacemakers and serves as a U.S. delegate to three International Standards Organization working groups. Mr. Sidebottom is active as an IEC observer in the work of the CEN/CENELEC joint working group on active implantable medical devices that is developing European standards under the auspices of the European Union. Mr. Sidebottom has spoken and written frequently on the subject of medical device labeling and is the author of *International Labeling Requirements for Medical Devices, Medical Equipment, and Diagnostic Products*.

Contents

INTRODUCTION

ix

Peter Blaisdell

ABOUT THE CONTRIBUTORS

xv

1. FINANCING STRATEGIES FOR SMALL DRUG DEVELOPERS 1

Matthew Frank

Fund-Raising	3
Public Financing	4
Early Funding Challenges	5
Conclusion	6

2. MANAGING BASIC RESEARCH IN THE TWENTY-FIRST CENTURY 7

Wolf-Dieter Busse

Business Challenges to Pharmaceutical Research Departments—A Summary 8

The Productivity Gap in Research and Development • The Financial Gap • The Innovation Gap • Premier Research Will Maintain Its Importance • Portfolio Management Continues to Be the Key Driver • The Search for Successful Horizontal Integration Continues • Focusing on Highly Competitive Therapeutic Segments • Protein Therapeutics Provide Important Solutions for Many Very Sick Patients • From the Genomics Age to the Post-Genomics Era • A New Vision: Pharmacogenomics • Gene and Cell Therapies Will Come . . . But to Which Level?

The New Biology in the Genomics Age 16

Gene Discovery and Validation Strategies in the Genomics Age • Polymorphisms and Disease-Specific Genotypes • Bioinformatics: Managing All the Data and Extracting Useful Information • Proteomics: Strategies for Protein Discovery • Functional Genomics • Molecular Pharmacology—a Bottleneck of Drug Discovery in the Genomics Age

Integration of High-Throughput Technology Platforms	29
<i>High-Throughput Screening • Combinatorial Chemistry • Gene Chips</i>	
Moving Toward the Post-Genomics Era: The New Research Process and Solutions for the "Longitude Problem"	35
<i>The "Longitude Problem" of the Genomics Age • The New High-Throughput Research Process • Pharmacogenomics-Based Discovery • Optimization Strategies and Preclinical Chemistry in the Post-Genomics Era</i>	
Protein Therapeutics	42
<i>The Rationale for Proteins as Drugs • The Disease Pyramid • Discovery of Novel Proteins and Peptides • Engineering of Proteins • Monoclonal Antibodies as Drugs • Low Attrition Rates and Short Development Times • The Impact of the Genomics Age • New Production Technologies</i>	
Gene Therapy	51
<i>Medical Need • The Status of Drug Development • Vectors and Delivery Systems • Targeting and Genes • Pricing and Commercial Success</i>	
Acknowledgment	58
References	59
 3. PROTECTING INTELLECTUAL PROPERTY IN THE NEW MILLENNIUM	 63
<i>Nadine Carol Chien</i>	
Methods of Securing Rights to Innovations	64
<i>Trade Secrets • Patents Patent Infringement • Patent Term • Inventorship</i>	
Obtaining Rights to Innovations	72
Patent and License Strategies for the Twenty-First Century	75
 4. THE MARKETING OF PHARMACEUTICAL PRODUCTS	 79
<i>Dimitris Dogramatzis</i>	
The Pharmaceutical Industry	79
Ethical Considerations in Pharmaceutical Marketing	82
<i>Money Waste • Intrusive • Manipulative • Lowers Healthcare Quality • Creates Social Inequality • Creates Unnecessary Demand</i>	
The Pharmaceutical Product Marketing Mix	84
<i>Product Place • Price • Promotion</i>	
Marketing Strategy	106
<i>From Worldwide Vision to Local Tactics • Strategic Planning</i>	
<i>The Pharmaceutical Marketing Environment</i> ¹¹²	
The Pharmaceutical Industry and the Internet	114
<i>Drug Dispensing over the Internet</i>	
Pharmaceutical Marketing Departments	119

Future Industry Trends	122
References	123
Further Reading	123
 5. REGULATORY AFFAIRS IN THE TWENTY-FIRST CENTURY	 129
<i>Meggi Raeder</i>	
From Discovery to First-in-Man Studies	130
<i>The IND Process • Interactions with the FDA • The Clinical Development Phase</i>	
Preparation of a New Drug Application or Biologics Licensing Application	134
<i>Electronic Submissions</i>	
Conducting Clinical Investigations Internationally	135
<i>Clinical Investigations in Europe • Marketing Applications</i>	
Worldwide Harmonization	136
Regulatory Resources	137
<i>The Role of Regulatory Affairs Personnel in Drug Development • Outsourcing • Regulatory Information—The Worldwide Web</i>	
Conclusions	139
References	141
 6. ADVANCES IN PRECLINICAL TOXICOLOGY STUDIES FOR PHARMACEUTICS	 143
<i>Larry E. Rodman</i>	
Regulatory Agencies and Guidelines for Toxicology Testing	144
Overview of Traditional Safety Studies for Pharmaceuticals	145
Toxicogenomics	148
<i>Microarrays and Oligoarrays in Preclinical Toxicogenomics</i>	
Toxicoproteomics	150
Biomarkers	151
<i>Biomarkers of Exposure • Biomarkers of Response or Effect • Biomarkers of Susceptibility</i>	
Alternative Animal Models in Preclinical Toxicology Studies	152
<i>Traditional Animal Models • Genetically Altered Animals • Application of Transgenic and Knockout Models in Preclinical Toxicology Studies</i>	
Nontraditional Techniques and Assays in Animal Toxicology Studies	156
Alternatives to Using Animal Models in Preclinical Toxicology Testing	158
Conclusions	159
References	160

7. DRUG PRODUCT FORMULATION DEVELOPMENT 163

Terry Dahl

Preformulation Activities	164
Analytical Considerations	166
Experimental Design	167
Formulation Development	168
<i>Parenteral Dosage Form Development • Liquid Oral Dosage Form Development • Solid Oral Dosage Form Development (Immediate-Release Tablets) • Solid Oral Dosage Form Development (Hard Gelatin Capsules) • Inhalation Dosage Form Development • Novel Drug Delivery Dosage Forms and Devices</i>	
Conclusion	197
References	198

8. TWENTY-FIRST CENTURY MANUFACTURING 205

Mark Pemberton

The Development Process	206
<i>Synthesis • Recovery and Purification • Formulation • Process Transfer</i>	
Manufacturing Operations	212
<i>Process Consistency and Change Control</i>	
Manufacturing Facilities	216
<i>GMP Compliance</i>	
Challenges in Biopharmaceutical Manufacturing	221
<i>Fermentation • Purification • Aseptic Filling and Lyophilization</i>	
Phases of Manufacturing	223
<i>Preclinical Development • Early Phase Clinical • Late Phase Clinical • Commercial • Outsourcing</i>	
Manufacturing in the Twenty-First Century	225
Conclusion	227
Acknowledgments	227
References	227

9. THE ART (AND SCIENCE) OF DEVELOPING A CLINICAL STRATEGY 229

Patrick J. Scannon

The Product/Indication Profile	234
<i>Label Information • Preclinical/Prior Clinical Status/Requirements • Clinical Proposal • Supporting Status/Requirements • Summary</i>	
The Global Strategic Plan	258